Entering text into the input field will update the search result below

FDA OKs Foundation Med's FoundationOne CDx as a companion Dx for Lynparza

Jul. 01, 2019 3:51 PM ETRoche Holding AG (RHHBY) StockBy: Douglas W. House, SA News Editor
  • The FDA has approved Roche (OTCQX:RHHBY +0.7%) unit Foundation Medicine's FoundationOne CDx molecular test as a companion diagnostic for AstraZeneca's Lynparza (olaparib) for first-line maintenance therapy in BRCA mutation-positive ovarian cancer.
  • The companies and Merck are also collaborating on developing companion diagnostics for Lynparza in prostate cancer.

Recommended For You

More Trending News

About RHHBY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RHHBY--
Roche Holding AG